+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Forecast 2024-2030- Product Image
Global Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5896414
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Branded Generics Market size was estimated at USD 432.30 billion in 2023, USD 494.29 billion in 2024, and is expected to grow at a CAGR of 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts.

Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector.

There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

Market Trends by Segment

  • Product: Significant adoption of value-added branded generics due to their additional advantages
  • Drug Type: High usage of anti-hypertensive for treating high blood pressure
  • Route of Administration: Wide adoption of oral route due to their longer duration of action
  • Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
  • Distribution Channel: Evolving online distribution channels for branded generics

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Vyvanse Generics Approved by FDA

The FDA has approved generic forms of Vyvanse - (Lisdexamfetamine Dimesylate) for the treatment option of ADHD in patients aged six years or older, as well as moderate-to-severe BED in adults. Takeda Pharmaceuticals' U.S. patent for Vyvanse expired, allowing companies to manufacture and sell generic versions of the medication. These generic versions may contain different binding agents, fillers, and colors.

Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement

The pan-Canadian Pharmaceutical Alliance (pCPA) & the Canadian Generic Pharmaceutical Association (CGPA) have renewed a three-year pricing initiative for generic medicines. This initiative aims to effectively manage public drug plan costs while providing a stable and predictable environment for generics manufacturers to introduce new drugs. As a part of the new initiative, any new generics entering the pan-Canadian Tiered Pricing Framework automatically reduce their prices to 55% of the brand reference price after three months, provided that there is only one generic product available in Canada.

Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics

Amneal Pharmaceuticals, Inc. introduced its authorized generic version of Xyrem1 (Sodium Oxybate) oral solution CIII in the United States. This medication is commonly prescribed to address cataplexy or excessive daytime sleepiness (EDS) by acting as a central nervous system depressant. In addition to this launch, Amneal has obtained Abbreviated New Drug Application (ANDA) approvals from the U.S. FDA for five complex generic products.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s.

This research report offers invaluable insights into various crucial aspects of the Branded Generics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
5.1.2. Restraints
5.1.2.1. Concerns associated with quality variations in branded generic medications
5.1.3. Opportunities
5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
5.1.4. Challenges
5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
5.2. Market Segmentation Analysis
5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
5.3. Market Trend Analysis
5.3.1. Availability of well-structured standards for branded generics in the Americas
5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Branded Generics Market, by Product
6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added
7. Branded Generics Market, by Drug Type
7.1. Introduction
7.2. Alkylating Agents
7.3. Anti-depressants
7.4. Anti-epileptics
7.5. Anti-hypertensive
7.6. Anti-psychotics
7.7. Antimetabolites
7.8. Hormones
7.9. Lipid Lowering Drugs
8. Branded Generics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical
9. Branded Generics Market, by Indication
9.1. Introduction
9.2. Acute & Chronic Pain
9.3. Cardiovascular Diseases
9.4. Dermatological Diseases
9.5. Gastrointestinal Diseases
9.6. Neurological Diseases
9.7. Oncology
10. Branded Generics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Americas Branded Generics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Branded Generics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Branded Generics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Vyvanse Generics Approved by FDA
14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
14.3.5. Dr Reddy’s Enters Trade Generics Business In Domestic Market
14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
14.3.8. Cipla Launches ‘Easylax L’,A Sugar-Free Oral Emulsion Laxative For Constipation Relief
14.3.9. Procaps Group to Acquire Grupo Somar from Advent International
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 81. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 82. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 83. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 84. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 85. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 86. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 87. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 88. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 89. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 93. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 94. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 95. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 98. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 99. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 100. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 101. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 102. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 103. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 115. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 116. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 117. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 118. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 119. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 120. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 127. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 128. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 129. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 130. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 131. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 132. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 133. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 134. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 135. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 136. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 137. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 138. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 139. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 140. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 142. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 144. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 146. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 148. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 150. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 152. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 154. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 155. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 156. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 157. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 158. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 159. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 160. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 161. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 162. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 163. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 164. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 165. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 166. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 167. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 168. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 169. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 170. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 171. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 172. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 173. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 174. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 175. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 176. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 177. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 178. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 179. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 180. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 181. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 182. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 183. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 184. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 185. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 186. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 187. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 188. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 189. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 190. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 191. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 192. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 193. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 194. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 195. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 196. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 197. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 198. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 199. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 200. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 201. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 202. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 203. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 204. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 205. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 206. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 207. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 208. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 209. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 210. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 211. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 212. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 213. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 214. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 215. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 216. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 217. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 218. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 219. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 222. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 223. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 224. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 225. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 226. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 227. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 228. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 229. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 230. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 231. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 232. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 233. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 234. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 235. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 236. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 237. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 238. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 239. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 240. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 241. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 242. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 243. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 244. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 245. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 246. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 247. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 248. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 249. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 250. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 251. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 252. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 253. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 254. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 255. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 256. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 257. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 258. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 259. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 260. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 261. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 262. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 263. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 264. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 265. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 266. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 267. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 268. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 269. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 270. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 271. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 272. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 273. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 274. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 275. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 276. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 277. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 278. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 279. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 280. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 281. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 282. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 283. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 284. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 285. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 286. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 287. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 288. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 289. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 290. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 291. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 294. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 295. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 296. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 297. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 298. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 313. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 314. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 315. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 316. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 317. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 318. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 319. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 320. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 321. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 322. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 323. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 324. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 325. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 326. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 327. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 328. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 329. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 330. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 331. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 332. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 333. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 334. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 335. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 336. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 337. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 338. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 339. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 340. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 341. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 342. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 343. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 344. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 345. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 346. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 347. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 348. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 349. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 350. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 351. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 352. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 353. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTR

Companies Mentioned

  • Abbott Laboratories
  • Ajanta Pharma Ltd.
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Endo International PLC
  • Eris Lifesciences Limited
  • Eva Pharma
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Lupin Limited
  • Micro Labs Limited
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zentiva Group, a.s.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 494.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 1126.43 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 155 Pages
  • Global
From
Branded Generics Global Market Report 2024 - Product Image

Branded Generics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 180 Pages
  • Global
From
Branded Generics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Branded Generics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 97 Pages
  • Global
From
2024 Global Forecast for Branded Generics (2025-2030 Outlook) - High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Branded Generics (2025-2030 Outlook) - High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From

About the Branded Generics Market

Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace. Branded generics are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace. Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.